Regenerative medicine and 3D bioprinting for human space exploration and planet colonisation

Tommaso Ghidini

European Space Agency, ESA-ESTEC, Noordwijk, The Netherlands

Correspondence to: Tommaso Ghidini. European Space Agency, ESA-ESTEC, Noordwijk, The Netherlands. Email: tommaso.ghidini@esa.int.

Abstract: 3D printing also known as additive manufacturing (AM) is seen as one of the key enabling technologies for a large number of high-end industrial sectors including the automotive, aerospace and medical industry. Recent advances and breakthroughs in the last years have enabled 3D printing of biocompatible materials, cells and supporting components into complex 3D functional living tissues. 3D bioprinting is being applied to regenerative medicine, addressing the need for tissues and organs suitable for transplantation. Bioprinting implies additional complexities related to the sensitivities of living cells such as printing parameters and conditions, material selection, cell types etc. Despite these challenges, beating artificial heart cells, cartilage implants, skin repairs, functional kidney tissues have been printed successfully on Earth. The present paper addresses the possibility of performing regenerative medicine in space, which may guarantee sustainable life support on long term/long distance planetary exploration missions, opening to stable planet colonisation.

Keywords: 3D bioprinting; regenerative medicine; space missions; human spaceflight; planet colonisation

Submitted Jan 18, 2018. Accepted for publication Feb 12, 2018.
doi: 10.21037/jtd.2018.03.19
View this article at: http://dx.doi.org/10.21037/jtd.2018.03.19

Introduction

Human spaceflight has undergone significant changes since its beginnings almost 50 years ago. With the establishment of the International Space Station (ISS) in low-Earth orbit (LEO), circling the earth at an altitude of around 400 km, crews sent into orbit have become larger and more heterogeneous and the duration of spaceflight has increased. To date, almost ninety crews have visited the ISS with a standard duration of each mission of around 6 months. Human missions beyond LEO refer to the Apollo Lunar programme, which was terminated in 1972, after a total of twelve astronauts had set foot on the surface of the Moon for a maximum of few days.

Today, human exploratory missions to the Moon or Mars, are widely considered as the next logical steps in human space exploration and, lately, colonisation. Almost all major national and international space agencies in the world as well as private investors and commercial initiatives are currently developing roadmaps and associated technologies to bring safely human beings to other planets in the solar system. Progressively, humanity shall get used to the concept of interplanetary travels among planets of our solar system, which shall become as natural as the concept of intercontinental flights on Earth. Human space flight will also see in the medium term a significantly increased number of travellers, longer durations of the flights, and longer distances up to stable permanence of human colonies on other planets. This will open to a number of challenges to be overcome, starting with ideological, but also political, technical, scientific, and even legal, philosophical, ethical and certainly medical.

The majority of the medical challenges faced during the human missions and associated durations performed so far, were mainly referring to radiations and micro- or reduced-gravity effects as well as psychological associated issues (1). Future exploratory missions to the Moon and Mars, including the establishment of permanently crewed base on the planet’s surface, will extend the distances travelled, the intensity of the radiation, the micro- and reduced-
gravity levels, the duration of the mission, and the levels of confinement and isolation to which the crews will be exposed. This will raise several health issues which may be limiting factors during these missions, in particular radiation health, gravity related effects and psychological issues. Crew health and performance have to be ensured during transfer flights and planetary surface exploration, including Extra Vehicular Activities (EVAs), and upon return to Earth. Particularly a mission to Mars poses even further challenges: the distance of the planet, the duration of the trip (at least 500 days) and the impossibility to abort the mission lead to the necessity for the mission to be completely self-sustainable, since no support from Earth can be received in case of a health or major technical contingency.

In this scenario, 3D bioprinting for regenerative medicine and ultimately organs reproduction and transplantation is considered by the European Space Agency (ESA) a long term enabling technology for distant planet exploration and colonisation.

3D printing, or additive manufacturing (AM) includes a large family of processes and technologies and can be applied to a very wide range of materials, ranging from metals, polymers and ceramics but also living cells and organs (2-9). 3D bioprinting has already been used for the generation and transplantation of several tissues, including multilayered skin, bone, vascular grafts, tracheal splints, heart tissue and cartilaginous structures. Other applications include developing high-throughput 3D-bioprinted tissue models for research, drug discovery and toxicology.

ESA has pioneered in the exploration of the currently available Earth based 3D bioprinting technologies with the aim of defining a strategic roadmap for the safe, reliable and sustainable utilisation of these technologies on planet, aiming at exploration and colonisation missions support. ESA’s long-term vision is presented in the present work.

**3D bioprinting—state of the art on Earth**

Regenerative medicine and tissue engineering aim at the development of functional biological tissue substitutes enhancing tissue reconstruction and regeneration. Alternatively, transplantation of stem cells is a promising approach with the potential of self-renewal and differentiation. The so called stem cells niche, is the complex 3D environment which influences the cells fates. Within this system cell-cell contacts, cell-matrix adhesion, and the exchange of growth factors and oxygen are required for stem cells regulation (10). Therefore the proper fabrication of niche-like environment is a key issue in stem cell biology and regenerative medicine (10-12). The production of stem cell niches and tissue constructs is very challenging from a technical point of view with respect to their complexity. A technology is needed that allows the generation of defined 3D microstructures copying original tissues templates. By this means there is a demand to develop natural substitutes instead of traditional 3D scaffolds (13,14), which often proved to be challenging since they limit oxygen exchange within the tissue. Moreover, the structure has to be formed out of a material that is not only compatible with the cells but also enables the exchange of nutrient and soluble factors. Further, material elasticity and forces have to be taken into account since these parameters are known to influence stem cells differentiation. Also, the cells have to be arranged in 3D, enabling the formation of close cell-cell as well as cell-matrix contacts and interactions. Lastly, cell differentiation has to be guided and controlled within this complex 3D system. As differentiation is dependent on the initial cell density, the cells constructs have to be formed out of a defined, variable, and high cells amount (15,16).

3D bioprinting is an AM technology, where cells and biomaterials such cytocompatible hydrogel precursors, often referred as bioink, are simultaneously deposited in a layer by layer manner to generate biologically active 3D tissues of predesigned shape and size. Different cells types can be placed at desired locations of the bioprinted element and high cells densities can be achieved (17-19). The bioink properties before, during and after gelation are essential to its printability, and are impacting the achievable structural resolution, the shape fidelity and the cell survival. However, it is the final properties of the matured bioprinted tissue construct or niche that are crucial for the end application. During tissue formation these properties are influenced by the amount of cells present in the construct, their proliferation, migration and interaction with the material.

During the last decades, computer-aided deposition of biological materials has been investigated as a potential technique for engineering of tissue regeneration or replacement. A number of very comprehensive reviews have been published and summarise all relevant technologies, possible materials and associated benefits and limitations (11,19-37). In general, all existing bioprinting approaches can be separated into three groups, as sketched in Figure 1, including inkjet bioprinting (piezoelectric and thermal), orifice-less bioprinting (laser-induced forward transfer, LIFT, and printing by surface acoustic waves) and extrusion.
bioprinting (pneumatic or mechanical).

**Inkjet bioprinting**

An inkjet bioprinter delivers small droplets of bioink (1–100 picoliters; 10–50 µm diameter) on predefined locations of a substrate. The two most common methods used for inkjet printing of cells are piezoelectric and thermal inkjet bioprinting (23,38). The piezoelectric inkjet printer uses piezoelectric crystals to produce acoustic waves forcing small amounts of liquid through the nozzle. The thermal inkjet system produces pulses of pressure by vaporising the bioink around the heating element and expelling the droplets out of the printing head. Inkjet bioprinters are successfully applied with a micrometer resolution (10–50 µm) for the deposition of cells and are compatible with a number of bioinks (38-40). However, the major drawback of this technology is the achievable low viscosity and low cells density (41,42), since high cells density and associated high viscosity of the bioinks could result in clogging of the printing head. On the other hand, high scanning speeds can be achieved.

**Orifice-free bioprinting**

Orifice free bioprinting can be further divided into laser-induced forward transfer (LIFT) and surface acoustic waves printing. In LIFT, a pulsed laser beam is focused and scanned over a donor substrate coated with an absorbing layer (e.g., titanium or gold) and a bioink layer (11,37,43-46). Focused laser pulses cause local evaporation of the absorbing layer thereby creating a high-pressure bubble propelling small portions of the bioink towards the collector platform. Since this bioprinting technique is orifice free, it is not affected by clogging problems. Very high precision can be achieved combined with high cells survivability, since shear stress and extrusion are avoided. The resolution is in the range of 10–100 µm and bioinks with a viscosity ranging from 1 to 300 mPa and medium cells densities of ~10^8 cells mL^-1 can be printed (31,47,48). The reduced scanning speed is the limiting factor of this technology.

Surface acoustic waves is the other orifice-free bioprinting method (49,50). Acoustic waves are produced by an acoustic ejector which uses a surface acoustic wave piezoelectric substrate (e.g., quartz, lithium niobate, etc.) with interdigitated gold rings placed on top of the substrate. The waves have a circular geometry, hence an acoustic focal plane is generated at the air-liquid interface in the microfluidic channel and bioink droplets are ejected from it. The diameter of the droplets is uniform and ranges from 3 to 200 µm by tuning the wavelength of the acoustic ejector. High cells viability is achieved and bioinks with various surface tensions and viscosities can be ejected and processed.

**Extrusion bioprinting**

Extrusion bioprinting is probably the most common method...
for the fabrication of 3D cell-laden constructs (51-53). The bioink is normally inserted in disposable plastic syringes and dispensed either mechanically or pneumatically (piston or screw based) on the receiving substrate. This technology releases rather large amount of hydrogel filaments in the order of 150–300 µm in diameter. High viscosity and cells densities can be achieved with this method, though with an increased risk of cells damage due to the mechanical interaction with the orifice and the associated shear stress. Nozzle clogging and a reduced resolution (in the order of 200–1,000 µm) are the recognised drawbacks of the process.

A new bioprinting approach is now proposed to improve the achievable environment for cells migration and spreading, currently suboptimal (54,55). In particular, a gel-in-gel bioprinting method bioink is extruded into a volume of self-healing hydrogel acting as a support material. The support hydrogel deforms after the injection of the bioink and heals immediately repairing and enclosing the printed structure inside. This method opens to multi-material printing, improves the mechanical properties of the construct and results in high cells viability.

Bioprinting has emerged in recent years as an attractive method for engineering of 3D tissues and organs in the laboratory, which can subsequently be implemented in a number of regenerative medicine applications. Currently, the primary goals of bioprinting are to (I) create complete replacements for damaged tissues in patients and (II) rapidly fabricate small-sized human-based tissue models or organoids for high-throughput diagnostics, pathology modelling, and drug development, examples of which are reported in Figure 2.

3D bioprinting has already been used for the generation and transplantation of several tissues, including multilayered skin, bone, vascular grafts, tracheal splints, heart tissue and cartilaginous structures. However, the capability of bioprinting fully functional complex tissues and organs still imply the resolution of a number of technical challenges (including e.g., the vascularisation, cells stability, production time and associated costs, capabilities of printing multi-materials, resolution vs. size of the print, cells viscosity and number, etc.), and addressing them requires the integration of technologies from the fields of engineering, biomaterials science, cell biology, physics and medicine.

ESA is considering this technology as a key enabler for long term/long distance missions, including planetary exploration and colonisation. This is particularly the case for the missions where the link with Earth will not be possible anymore and full mission self-sustainability shall be guaranteed.

**Why other planets?**

After the realisation of the ISS, human exploratory missions to the Moon or Mars, are widely considered as the next logical steps in human space exploration and, lately, colonisation. The ISS is the first example of an international cooperation for the joint development, operation and utilisation of a permanent space habitat in LEO. Hence, with the ISS a new era of peaceful cooperation in space on a global scale has started. Major partners are the USA, Russia, Japan, Europe and Canada. The experience matured with the ISS has shown that human beings can live, operate and perform science in space and that this can be done peacefully. The next logical step is to build on the technological, human, scientific and political lessons learnt matured in this endeavour and start bringing humanity to live, operate and perform science in other planets and in a permanent manner. The benefits and opportunities of exploring and eventually establishing permanent outposts on other planets (e.g., the Moon and Mars) are tremendous as described in (56) and reported here. They include:

- Determine if life is or was present outside of Earth and understand the environments that supported or could support it;
- Extend the human presence, exploring a variety of destinations beyond LEO with a focus on continuously increasing the number of individuals...
than can be supported at these destinations, the
duration of time that individuals can remain at these
destinations, and the level of self-sufficiently;

- Develop the necessary level of exploration
technologies and capabilities: this shall include the
knowledge, the capabilities, and the infrastructure
required to live and work at destination beyond
LEO through development and testing of advanced
technologies, reliable systems, and efficient
operations scenarios in an off-Earth environment;

- Perform science to support human exploration.
Reduce the risk and increase the productivity of
future missions in our solar system by characterising
the effect of the space environment on human health
and exploration systems;

- Provide other survivability options and resources to
humankind beyond Earth;

- Stimulate economic expansion. Support and
courage the provision of technology, systems,
hardware and services for commercial entities and
create new markets based on space activities that will
return economic, technological, and quality-of-life
benefits for the whole humankind;

- Perform space, Earth and applied science. Engage
in science investigations of, and from, solar system
destinations and conduct applied science in the
unique environment of solar system destinations;

- Provide opportunities for the public to engage
interactively in space exploration;

- Enhance Earth safety. Enhance the safety of Earth
by understanding the degradation processes of other
(similar) planets, by following collaborative pursuit
of planetary defence and orbital debris management
mechanisms.

In support of the vision described above, a number of
activities are ongoing and are currently paving the way
for human planetary exploration and colonisation. In the
following a number of the most relevant developments
presently supporting the realisation of long term stable
mission on the Mars surface are briefly described.

The recent decision by the ISS partners to extend its life
until at least 2020 ensures that the ISS can be effectively
further used to prepare for exploration, covering human
science, engineering, biology and chemistry.

The current ongoing development of the Multi-Purpose
Crew Vehicle (MPCV), part of the Orion program. Orion is
NASA’s next spacecraft to send humans into space (Figure 3).

It is designed to send astronauts further into space than ever
before, beyond the Moon to asteroids and even Mars. ESA has
designed and is overseeing the development of Orion’s service
module, the part of the spacecraft that supplies air, electricity
and propulsion. Much like a train engine pulls passenger
carriages and supplies power, the European Service Module
will take the Orion capsule to its destination and back.

The intention to realise the Deep Space Gateway
(Figure 4). The project envisions a modular spacecraft
with an open architecture orbiting the Moon in the mid
2020s. Acting as a hub in the lunar vicinity, the platform is
intended to be a staging post to multiple destinations. It will
launch missions to the lunar surface, into deep space and
ultimately to Mars (S8).

Robotic missions have always served as the precursors to
human exploration missions. Precursor robotic missions are
essential to ensure human health, safety and the success of
human missions and ensure maximum return of investments
required for subsequent human exploration. A completely

Figure 3 (A) Artist impression of the MPCV vehicle with the deployed solar array and the European Space Agency service module visible; (B)
MPCV capsule during integration phases. MPCV, Multi-Purpose Crew Vehicle.
European manufactured rover (Figure 5), is part of the 2020 mission of the ExoMars programme that will also deliver a Russian surface platform to Mars. The rover will be the first mission to combine the capability to move across the surface and to study Mars at depth. It will collect samples with a drill down to a depth of 2 m and analyse them with next-generation instruments in an onboard laboratory. Underground samples are more likely to include biomarkers, since the tenuous martian atmosphere offers little protection from radiation and photochemistry at the surface. The primary objective is to land the rover at a site with high potential for finding well-preserved organic material, particularly from the very early history of the planet. The rover is expected to travel several kilometres during its mission.

ESA is also currently working on the building blocks technologies which will be required for the realisation of stable and sustainable human outposts on the Moon (57,59) and Mars (60), leveraging and maximising in-situ resources utilisation (ISRU) and mission self-sustainability.

The described missions constitute highly relevant technology building blocks for the development of a stable base on the Moon or on Mars.

However, for the realisation of a mission of these proportions the first challenge to be solved will be mainly a political one. Seen the level of financial, technological, scientific effort required, consensus shall be established among a wide range of nations, including Europe, the USA, Russia, but also China, India, Japan, Canada. Moreover, partnerships shall be established not only among institutional national and international space agencies, but it shall also be extended to the private sectors, where commercial initiatives are blossoming.

### The space medical challenges and possible mission scenarios

A number of significant medical challenges are associated with human spaceflight and are linked to a set of factors,
starting with the distance and the duration of the space journey. In particular the following issues play a major role in astronauts’ health during space flight:

- Radiation exposure (in terms of intensity, type of the radiating particles and irradiation time), mainly leading to neoplastic risk, central nervous system effects, cataracts, circulatory diseases and acute radiation syndromes (61-66);
- Reduced gravity levels, mainly leading to loss of muscles/bones mass, reduced cardiovascular activity, haematopoiesis and lymphopoiesis decrease, changing of motorial functions, visu’s reduction, wound healing capabilities reduction;
- Injures and burns due to missions’ hazards and contingencies;
- Psychological aspects.

In Table 1, a more detailed list of general health challenges and the associated probabilities during three different mission scenarios and durations to the Moon and to Mars is presented (1).

For the current missions’ scenarios and durations, mainly referring to the ISS in LEO, the above listed medical issues are mitigated by dedicated countermeasures, including:

- Materials for radiation protection are used on the ISS structures;
- Definition of radiation thresholds (and associated flight limitations for astronauts exceeding them) based on blood generating organs levels;
- Physical training of astronauts during their permanence in space.

Medical contingencies on-board of the ISS are currently treated as first-aid interventions. All astronauts are trained to perform first-aid and patient stabilisation. No surgery is performed, but all serious patients can be stabilised and reach a hospital on Earth for further specialised treatment within 20 hours.

A similar approach will be adopted for medical issues occurring on a Moon base, where no surgery will most probably be performed. Also, in this case, seriously ill astronauts will be returned to Earth’s based hospitals which can be reached in 3 to 4 days. Moreover, the establishment of a permanent Moon base will offer further opportunities to mitigate the radiations associated risks as well as the reduced gravity related issues. In particular, the Base structure can be manufactured such that radiation shielding is provided by the base walls and water present in their interstices. Moreover, dedicated physical training centres can be foreseen to counteract reduced gravity effects on human bones and muscles experience in the Moon’s reduced gravity.

If humans have to travel farer distances from the Moon and establish Mars permanent bases, different mission scenarios and strategies shall be envisaged. The Mars distance and the associated mission’s duration (at least 500 days) with no abortion possibility (due to astrodynamics conditions during the flight) will not allow the travellers with serious medical contingencies to be safely returned to Earth in reasonable time. Regenerative medicine and potentially 3D bioprinting shall be adopted (67-69), depending on mission duration and medical personnel and support infrastructure availability.

In particular, the following Mars mission scenarios can be anticipated:

(I) first Mars mission:

- Preliminary exploratory mission of short duration (500 days);
- Limited crew (4 to 5 astronauts);
- Medical surgeon on board with generic and broad capabilities;
- Although astronauts will be selected based on their strong medical health and genetics, skin burns and bones injures may occur due to mission contingencies;
- Hence, 3D bioprinting of skin and bones shall be considered however medical personnel and infrastructure limitations will confine its applications to small and superficial interventions;

(II) long term Mars mission/settlement:

- Longer term Mars missions up to human stable settlement (from 2 to 5 years and above);
- Larger crew (more than twenty astronauts);
- Medical and surgical infrastructure available;
- Generalist surgeon trained based on a surgical skills maintenance program using tele-training capabilities and augmented reality (telemedicine not possible due to Earth/Mars data transmission delay);
- 3D bioprinting capabilities considered mission enabling, for applications ranging from skin and bones up to tissues and organs implantation;
- Long term vision includes CT scanning of astronauts organs and stem cells support for organ reproduction in case of damage/failure on planet.

Adopting 3D bioprinting on a planet or in space
### Table 1 Probabilities of occurrence of general health issues during three mission scenarios [source (1)].

<table>
<thead>
<tr>
<th>General health challenge</th>
<th>Scenario 1 (180 days Moon mission)</th>
<th>Scenario 2 (1,000 days Mars mission)</th>
<th>Scenario 3 (500 days Mars mission)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>On board the transfer vehicle</td>
<td>On surface of the Moon</td>
<td>On board the transfer vehicle</td>
</tr>
<tr>
<td>Intestinal infectious diseases</td>
<td>AR</td>
<td>0.01</td>
<td>0.006</td>
</tr>
<tr>
<td>Non-zoonotic bacterial diseases</td>
<td>AR</td>
<td>AR</td>
<td>0.01</td>
</tr>
<tr>
<td>Viral diseases</td>
<td>AR</td>
<td>AR</td>
<td>0.01</td>
</tr>
<tr>
<td>Venereal diseases</td>
<td>AR</td>
<td>AR</td>
<td>0.01</td>
</tr>
<tr>
<td>Acute respiratory infections</td>
<td>0.35</td>
<td>7.9</td>
<td>39.3</td>
</tr>
<tr>
<td>Pneumonia and influenza</td>
<td>AR</td>
<td>0.02</td>
<td>0.1</td>
</tr>
<tr>
<td>Bronchitis (asthma included)</td>
<td>0.004</td>
<td>0.02</td>
<td>0.01</td>
</tr>
<tr>
<td>Cystitis</td>
<td>0.08</td>
<td>1.8</td>
<td>8.8</td>
</tr>
<tr>
<td>Infections of skin and subcutaneous tissue</td>
<td>0.08</td>
<td>1.8</td>
<td>8.8</td>
</tr>
<tr>
<td>Neoplasm (pre and post flight control)</td>
<td>AR</td>
<td>AR</td>
<td>0.008</td>
</tr>
<tr>
<td>Endocrine, nutritional, metabolic, immunity</td>
<td>AR</td>
<td>0.006</td>
<td>0.03</td>
</tr>
<tr>
<td>Disorder of thyroid gland</td>
<td>AR</td>
<td>AR</td>
<td>0.002</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>AR</td>
<td>AR</td>
<td>0.004</td>
</tr>
<tr>
<td>Nutritional deficiencies (avoid by adequate nutrition)</td>
<td>AR</td>
<td>AR</td>
<td>AR</td>
</tr>
<tr>
<td>Obesity</td>
<td>AR</td>
<td>AR</td>
<td>AR</td>
</tr>
<tr>
<td>Diseases of blood and BFO</td>
<td>AR</td>
<td>0.004</td>
<td>0.02</td>
</tr>
<tr>
<td>Cardiovascular disease</td>
<td>AR</td>
<td>0.02</td>
<td>0.1</td>
</tr>
<tr>
<td>Hypertensive disease</td>
<td>AR</td>
<td>0.002</td>
<td>0.01</td>
</tr>
<tr>
<td>Ischaemic heart disease</td>
<td>AR</td>
<td>0.008</td>
<td>0.04</td>
</tr>
<tr>
<td>Hemorrhoids</td>
<td>AR</td>
<td>0.02</td>
<td>0.1</td>
</tr>
<tr>
<td>Digestive disease</td>
<td>0.004</td>
<td>0.1</td>
<td>0.5</td>
</tr>
<tr>
<td>Appendicitis</td>
<td>AR</td>
<td>0.006</td>
<td>0.03</td>
</tr>
<tr>
<td>Peptic ulcers</td>
<td>AR</td>
<td>0.002</td>
<td>0.01</td>
</tr>
<tr>
<td>Abdominal hernia</td>
<td>AR</td>
<td>0.01</td>
<td>0.04</td>
</tr>
<tr>
<td>Disease of liver &amp; gall bladder</td>
<td>AR</td>
<td>0.01</td>
<td>0.05</td>
</tr>
<tr>
<td>Urinary calculus</td>
<td>AR</td>
<td>0.004</td>
<td>0.02</td>
</tr>
<tr>
<td>Disease of male genital organs</td>
<td>AR</td>
<td>0.004</td>
<td>0.02</td>
</tr>
<tr>
<td>Orchitis and epididymitis</td>
<td>AR</td>
<td>0.003</td>
<td>0.01</td>
</tr>
<tr>
<td>Diseases of breast and female organs</td>
<td>0.004</td>
<td>0.1</td>
<td>0.5</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>AR</td>
<td>0.01</td>
<td>0.05</td>
</tr>
<tr>
<td>Fracture of skull</td>
<td>AR</td>
<td>0.004</td>
<td>0.02</td>
</tr>
</tbody>
</table>

Table 1 (continued)
<table>
<thead>
<tr>
<th>General health challenge</th>
<th>Scenario 1 (180 days Moon mission)</th>
<th>Scenario 2 (1,000 days Mars mission)</th>
<th>Scenario 3 (500 days Mars mission)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>On board the transfer vehicle</td>
<td>On surface of the Moon</td>
<td>On board the transfer vehicle</td>
</tr>
<tr>
<td>Fracture of spine and trunk</td>
<td>AR 0.004</td>
<td>0.02</td>
<td>0.01 AR</td>
</tr>
<tr>
<td>Fracture of upper limb</td>
<td>AR 0.01</td>
<td>0.06</td>
<td>0.04 0.002</td>
</tr>
<tr>
<td>Fracture of lower limb</td>
<td>AR 0.006</td>
<td>0.03</td>
<td>0.02 AR</td>
</tr>
<tr>
<td>Dislocation</td>
<td>AR 0.01</td>
<td>0.05</td>
<td>0.03 0.002</td>
</tr>
<tr>
<td>Sprains and strains</td>
<td>0.006</td>
<td>0.13</td>
<td>0.4 0.03</td>
</tr>
<tr>
<td>Head injury</td>
<td>AR 0.004</td>
<td>0.02</td>
<td>0.01 0.004</td>
</tr>
<tr>
<td>Open wounds</td>
<td>AR 0.02</td>
<td>0.1</td>
<td>0.06 0.004</td>
</tr>
<tr>
<td>Superficial injury</td>
<td>AR 0.02</td>
<td>0.1</td>
<td>0.06 0.004</td>
</tr>
<tr>
<td>Contusion</td>
<td>0.002</td>
<td>0.04</td>
<td>0.1 0.007</td>
</tr>
<tr>
<td>Crushing injury</td>
<td>AR 0.02</td>
<td>0.1</td>
<td>0.06 0.003</td>
</tr>
<tr>
<td>Foreign bodies</td>
<td>AR 0.02</td>
<td>0.1</td>
<td>0.06 0.003</td>
</tr>
<tr>
<td>Burns</td>
<td>AR 0.02</td>
<td>0.1</td>
<td>0.06 0.003</td>
</tr>
<tr>
<td>Diseases of ear and mastoid process</td>
<td>AR 0.02</td>
<td>0.1</td>
<td>0.06 0.003</td>
</tr>
<tr>
<td>Dental diseases</td>
<td>AR 0.02</td>
<td>0.1</td>
<td>0.06 0.003</td>
</tr>
<tr>
<td>Arthropathies and related disorders</td>
<td>0.002</td>
<td>0.04</td>
<td>0.2 0.006</td>
</tr>
<tr>
<td>Dorsopathies</td>
<td>0.002</td>
<td>0.04</td>
<td>0.2 0.006</td>
</tr>
<tr>
<td>Congenital anomalies</td>
<td>AR AR 0.01</td>
<td>0.01 0.006</td>
<td>0.007 AR</td>
</tr>
<tr>
<td>Psychoses</td>
<td>AR 0.004</td>
<td>0.02</td>
<td>0.01 0.015 AR</td>
</tr>
<tr>
<td>Neurotonic disorders</td>
<td>AR 0.02</td>
<td>0.1</td>
<td>0.06 0.003</td>
</tr>
<tr>
<td>Alcoholic dependence syndrome</td>
<td>AR 0.01</td>
<td>0.05</td>
<td>0.03 0.035 0.002</td>
</tr>
<tr>
<td>Poisoning</td>
<td>AR 0.004</td>
<td>0.02</td>
<td>0.01 0.01 AR</td>
</tr>
<tr>
<td>Toxic effects</td>
<td>AR 0.01</td>
<td>0.05</td>
<td>0.03 0.04 0.002</td>
</tr>
<tr>
<td>Reduced temperature effects</td>
<td>AR 0.01</td>
<td>0.05</td>
<td>0.03 0.001</td>
</tr>
<tr>
<td>Heat and light effects</td>
<td>AR 0.01</td>
<td>0.07</td>
<td>0.04 0.002</td>
</tr>
</tbody>
</table>

AR, accepted risk, because the probability of occurrence is too low (<0.001); BFO, blood forming organs.

(ideally also during the travel to reach the target planet) implies significant further challenges to be solved, with respect to the already open ones on Earth. In particular, the detrimental effects of radiation and microgravity on both the patients to be treated as well as the stem cells. Also, microgravity and/or reduced gravity will limit the bioprinting capabilities of the printer itself. Moreover, bio-printer shall be used in conjunction with sterile production areas, cells culturing and incubators systems as well as dedicated surgical infrastructures. Also specific pharmacological treatment ad or anaesthesia may be designed based on resources available on planet.

ESA has pioneered the addressing of all the above listed challenges within its vision of adopting 3D bioprinting and regenerative medicine for long term planet colonisation missions. In particular, the Agency has just kicked off the
first study in this domain in which the following aspects will be analysed and consolidated (70):

- The definition of a concept for the utilisation (including clinical scenarios) of 3D bioprinting of living tissues as a technology to sustain life on long term/long distance human exploration missions and planetary colonisation;
- The definition of the requirements for 3D bioprinting of living tissues in the frame of manned space missions and planetary colonisation;
- The discussion of key domains (e.g., sensitivities of living cells such as printing parameters and conditions, materials selection, cell types etc.) of relevance for 3D bioprinting of living tissues but also specific to in-space/in-planet utilisation (e.g., covering radiation, micro- and reduced-gravity, limited resources availability, etc.) to be further investigated;
- The discussion of solutions and technologies (existing or to be developed);
- The identification of potential applicable regulations and norms (including safety aspects) regarding the performance of 3D bioprinting in space;
- The discussion of a preliminary accommodation concept for the realisation of an operating theatre in a space environment for 3D bioprinting and surgical implantation;
- The manufacturing of a tissue demonstrator, to be performed under space/planet representative conditions.

Conclusions

In the present paper, ESA’s vision related to the implementation of 3D bioprinting technologies for long-term/long-distance human space missions has been presented, and the following can be summarised:

(I) humanity has the opportunity for the first time in its history to fly farer in the solar system than ever before, but also it has the potential technologies for establishing permanent outposts on the Moon and on Mars surfaces;

(II) if a Mars outpost is conceived, the nature of the mission (including distance from Earth, impossibility of mission abortion during flight to and/or from planet) requires a fully self-sustainable mission concept, especially with respect to medical aspects;

(III) once appropriate medical and surgical infrastructure can be guaranteed on the planet surface, ESA considers 3D bioprinting as mission enabling, for applications ranging from skin and bones up to tissues and organs implantation;

(IV) ESA is pioneering in addressing all associated challenges with the vision of safe, reliable and sustainable utilisation of 3D bioprinting and regenerative medicine for long term planet colonisation missions in the first exploratory study of this kind in Europe (70);

(V) the benefit of space research and technology developments may stimulate, as it is often the case in other scientific areas (71), an increased sensitisation and return of investment on Earth based development.

Acknowledgements

None.

Footnote

Conflicts of Interest: The author has no conflicts of interest to declare.

References

Fatigue properties of AlSi10Mg obtained by additive manufacturing: Defect-based modelling and prediction of fatigue strength. Eng Fract Mech 2018;187:165-89.
69. Ghidini T. New Materials to Improve Efficacy and Safety: Lessons Learnt from the European Space Agency.


Cite this article as: Ghidini T. Regenerative medicine and 3D bioprinting for human space exploration and planet colonization. J Thorac Dis 2018;10(Suppl 20):S2363-S2375. doi: 10.21037/jtd.2018.03.19